{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T04:59:36Z","timestamp":1769921976371,"version":"3.49.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:00:00Z","timestamp":1761091200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:00:00Z","timestamp":1761091200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-025-11710-y","type":"journal-article","created":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:47:36Z","timestamp":1761119256000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Decline in estimated glomerular filtration rate following substitution of Nevirapine-based regimen with Tenofovir-based regimen in Indonesia"],"prefix":"10.1186","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6650-0559","authenticated-orcid":false,"given":"Evy","family":"Yunihastuti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5045-6562","authenticated-orcid":false,"given":"Pringgodigdo","family":"Nugroho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9599-1825","authenticated-orcid":false,"given":"Muhammad","family":"Yusuf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salfia Dian","family":"Lastari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fadlika","family":"Harinda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiara Kumala","family":"Putri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meivina Ramadhani","family":"Pane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Metra Adi","family":"Pratama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mira","family":"Yulianti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alvina","family":"Widhani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6951-1480","authenticated-orcid":false,"given":"Suzy","family":"Maria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4331-2381","authenticated-orcid":false,"given":"Anshari Saifuddin","family":"Hasibuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7505-0289","authenticated-orcid":false,"given":"Maruhum Bonar Hasiholan","family":"Marbun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7941-7743","authenticated-orcid":false,"given":"Sukamto","family":"Koesnoe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teguh Harjono","family":"Karjadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,22]]},"reference":[{"issue":"2","key":"11710_CR1","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1111\/bcp.12403","volume":"79","author":"A Tseng","year":"2015","unstructured":"Tseng A, Seet J, Phillips EJ. The evolution of three decades of antiretroviral therapy: challenges, triumphs and the promise of the future. Br J Clin Pharmacol. 2015;79(2):182.","journal-title":"Br J Clin Pharmacol"},{"issue":"27","key":"11710_CR2","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa2108793","volume":"385","author":"A Turkova","year":"2021","unstructured":"Turkova A, White E, Mujuru HA, Kekitiinwa AR, Kityo CM, Violari A, et al. Dolutegravir as first- or second-line treatment for HIV-1 infection in children. N Engl J Med. 2021;385(27):2531\u201343.","journal-title":"N Engl J Med"},{"issue":"4","key":"11710_CR3","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1177\/2040622314530461","volume":"5","author":"A Fantauzzi","year":"2014","unstructured":"Fantauzzi A, Mezzaroma I. Dolutegravir: clinical efficacy and role in HIV therapy. Ther Adv Chronic Dis. 2014;5(4):164.","journal-title":"Ther Adv Chronic Dis"},{"key":"11710_CR4","unstructured":"Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV: interim guidelines. Supplement to the 2016 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection [Internet]. 2018 [cited 2024 Feb 11]. Available from: https:\/\/www.who.int\/publications\/i\/item\/WHO-CDS-HIV-18.51"},{"issue":"5","key":"11710_CR5","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1111\/bcp.16009","volume":"90","author":"R Mpofu","year":"2024","unstructured":"Mpofu R, Kawuma AN, Wasmann RE, Akpomiemie G, Chandiwana N, Sokhela SM, et al. Determinants of early change in serum creatinine after initiation of dolutegravir-based antiretroviral therapy in South Africa. Br J Clin Pharmacol. 2024;90(5):1247\u201357.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"11710_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/1742-6405-11-35","volume":"11","author":"SG Holt","year":"2014","unstructured":"Holt SG, Gracey DM, Levy MT, Mudge DW, Irish AB, Walker RG, et al. A consensus statement on the renal monitoring of Australian patients receiving Tenofovir based antiviral therapy for HIV\/HBV infection. AIDS Res Ther. 2014;11(1):35.","journal-title":"AIDS Res Ther"},{"issue":"1","key":"11710_CR7","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s12882-022-02721-x","volume":"23","author":"R Shi","year":"2022","unstructured":"Shi R, Chen X, Lin H, Ding Y, He N. Incidence of impaired kidney function among people with HIV: a systematic review and meta-analysis. BMC Nephrol. 2022;23(1):107.","journal-title":"BMC Nephrol"},{"key":"11710_CR8","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.ijid.2020.01.035","volume":"93","author":"X Tao","year":"2020","unstructured":"Tao X, Lu Y, Zhou Y, Zhang L, Chen Y. Efficacy and safety of the regimens containing Tenofovir Alafenamide versus Tenofovir disoproxil fumarate in fixed-dose single-tablet regimens for initial treatment of HIV-1 infection: a meta-analysis of randomized controlled trials. Int J Infect Dis. 2020;93:108\u201317.","journal-title":"Int J Infect Dis"},{"issue":"10","key":"11710_CR9","doi-asserted-by":"publisher","first-page":"3835","DOI":"10.1093\/ndt\/gfs263","volume":"27","author":"TC Turin","year":"2012","unstructured":"Turin TC, Coresh J, Tonelli M, Stevens PE, De Jong PE, Farmer CKT, et al. Short-term change in kidney function and risk of end-stage renal disease. Nephrol Dial Transplant. 2012;27(10):3835\u201343.","journal-title":"Nephrol Dial Transplant"},{"key":"11710_CR10","doi-asserted-by":"crossref","unstructured":"Turin TC, James MT, Jun M, Tonelli M, Coresh J, Manns BJ, et al. Short-term change in eGFR and risk of cardiovascular events. J Am Heart Assoc. 2014;3(5):e000997.","DOI":"10.1161\/JAHA.114.000997"},{"issue":"9","key":"11710_CR11","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH, Zhang Y, Castro AF, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604\u201312.","journal-title":"Ann Intern Med"},{"issue":"7","key":"11710_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0022661","volume":"6","author":"T Nishijima","year":"2011","unstructured":"Nishijima T, Komatsu H, Gatanaga H, Aoki T, Watanabe K, Kinai E, et al. Impact of small body weight on Tenofovir-associated renal dysfunction in HIV-infected patients: a retrospective cohort study of Japanese patients. PLoS ONE. 2011;6(7):e22661.","journal-title":"PLoS ONE"},{"key":"11710_CR13","doi-asserted-by":"crossref","unstructured":"Chaisiri K, Bowonwatanuwong C, Kasettratat N, Kiertiburanakul S. Incidence and risk factors for tenofovir-associated renal function decline among Thai HIV-infected patients with low-body weight. Curr HIV Res [Internet]. 2010 Nov 26 [cited 2025 Mar 5];8(7):504\u20139. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/21073439\/","DOI":"10.2174\/157016210793499259"},{"key":"11710_CR14","doi-asserted-by":"crossref","unstructured":"Bash LD, Coresh J, K\u00f6ttgen A, Parekh RS, Fulop T, Wang Y et al. Defining incident chronic kidney disease in the research setting: The ARIC Study. Am J Epidemiol [Internet]. 2009 Aug [cited 2025 Mar 5];170(4):414\u201324. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/19535543\/","DOI":"10.1093\/aje\/kwp151"},{"key":"11710_CR15","doi-asserted-by":"crossref","unstructured":"Chue CD, Edwards NC, Davis LJ, Steeds RP, Townend JN, Ferro CJ. Serum phosphate but not pulse wave velocity predicts decline in renal function in patients with early chronic kidney disease. Nephrol Dial Transplant [Internet]. 2011 Aug [cited 2025 Mar 5];26(8):2576\u201382. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/21248296\/","DOI":"10.1093\/ndt\/gfq787"},{"issue":"9403","key":"11710_CR16","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S0140-6736(03)15268-3","volume":"363","author":"C Nishida","year":"2004","unstructured":"Nishida C, Barba C, Cavalli-Sforza T, Cutter J, Deurenberg P, Darnton-Hill I, et al. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004;363(9403):157\u201363.","journal-title":"Lancet"},{"key":"11710_CR17","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25324","author":"OQ Goh","year":"2019","unstructured":"Goh OQ, Colby DJ, Pinyakorn S, Sacdalan C, Kroon E, Chan P, et al. Switch to dolutegravir is well tolerated in Thais with HIV infection. J Int AIDS Soc. 2019. https:\/\/doi.org\/10.1002\/jia2.25324.","journal-title":"J Int AIDS Soc"},{"key":"11710_CR18","doi-asserted-by":"crossref","unstructured":"Nishijima T, Gatanaga H, Komatsu H, Tsukada K, Shimbo T, Aoki T et al. Renal Function Declines More in Tenofovir- than Abacavir-Based Antiretroviral Therapy in Low-Body Weight Treatment-Na\u00efve Patients with HIV Infection. PLoS One [Internet]. 2012 Jan 5 [cited 2025 Mar 5];7(1):e29977. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC3252345\/","DOI":"10.1371\/journal.pone.0029977"},{"key":"11710_CR19","first-page":"308","volume":"71","author":"H Moon Koh","year":"2016","unstructured":"Moon Koh H, Kumar S. Tenofovir-induced nephrotoxicity: a retrospective cohort study. Med J Malaysia. 2016;71:308.","journal-title":"Med J Malaysia"},{"key":"11710_CR20","doi-asserted-by":"crossref","unstructured":"Lee JE, Lee S, Song SH, Kwak IS, Lee SH. Incidence and risk factors for tenofovir-associated nephrotoxicity among human immunodeficiency virus-infected patients in Korea. Korean J Intern Med [Internet]. 2019 Mar 1 [cited 2025 Mar 5];34(2):409\u201317. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/29020764\/","DOI":"10.3904\/kjim.2016.418"},{"key":"11710_CR21","doi-asserted-by":"crossref","unstructured":"Nishijima T, Kawasaki Y, Tanaka N, Mizushima D, Aoki T, Watanabe K et al. Long-term exposure to tenofovir continuously decrease renal function in HIV-1-infected patients with low body weight: results from 10 years of follow-up. AIDS [Internet]. 2014 Aug 24 [cited 2025 Mar 5];28(13):1903\u201310. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/25259702\/","DOI":"10.1097\/QAD.0000000000000347"},{"key":"11710_CR22","doi-asserted-by":"crossref","unstructured":"Nishijima T, Kurosawa T, Tanaka N, Kawasaki Y, Kikuchi Y, Oka S et al. Urinary \u03b22 microglobulin can predict tenofovir disoproxil fumarate-related renal dysfunction in HIV-1-infected patients who initiate tenofovir disoproxil fumarate-containing antiretroviral therapy. AIDS [Internet]. 2016 Jun 19 [cited 2025 Mar 5];30(10):1563\u201371. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/26919734\/","DOI":"10.1097\/QAD.0000000000001070"},{"issue":"4","key":"11710_CR23","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1111\/j.1365-2125.2012.04440.x","volume":"75","author":"J Koteff","year":"2013","unstructured":"Koteff J, Borland J, Chen S, Song I, Peppercorn A, Koshiba T, et al. A phase 1 study to evaluate the effect of dolutegravir on renal function via measurement of Iohexol and para-aminohippurate clearance in healthy subjects. Br J Clin Pharmacol. 2013;75(4):990\u20136.","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"11710_CR24","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1124\/dmd.112.048918","volume":"41","author":"MJ Reese","year":"2013","unstructured":"Reese MJ, Savina PM, Generaux GT, Tracey H, Humphreys JE, Kanaoka E, et al. In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor. Drug Metab Dispos. 2013;41(2):353\u201361.","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"11710_CR25","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1111\/tid.12545","volume":"18","author":"DH Lee","year":"2016","unstructured":"Lee DH, Malat GE, Bias TE, Harhay MN, Ranganna K, Doyle AM. Serum creatinine elevation after switch to dolutegravir in a human immunodeficiency virus-positive kidney transplant recipient. Transpl Infect Dis. 2016;18(4):625.","journal-title":"Transpl Infect Dis"},{"issue":"9","key":"11710_CR26","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1056\/NEJMoa1902824","volume":"381","author":"WDF Venter","year":"2019","unstructured":"Venter WDF, Moorhouse M, Sokhela S, Fairlie L, Mashabane N, Masenya M, et al. Dolutegravir plus two different prodrugs of tenofovir to treat HIV. N Engl J Med. 2019;381(9):803\u201315.","journal-title":"N Engl J Med"},{"key":"11710_CR27","doi-asserted-by":"crossref","unstructured":"Venter WDF, Fabian J, Feldman C. An overview of Tenofovir and renal disease for the HIV-treating clinician. South Afr J HIV Med. 2018;19(1):817.","DOI":"10.4102\/sajhivmed.v19i1.817"},{"key":"11710_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jve.2021.100028","author":"L Waters","year":"2021","unstructured":"Waters L, Mehta V, Gogtay J, Boffito M. The evidence for using Tenofovir disoproxil fumarate plus lamivudine as a nucleoside analogue backbone for the treatment of HIV. J Virus Erad. 2021. https:\/\/doi.org\/10.1016\/j.jve.2021.100028.","journal-title":"J Virus Erad"},{"key":"11710_CR29","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.2147\/IDR.S451346","volume":"17","author":"M Deng","year":"2024","unstructured":"Deng M, Chen N, Lao X, Wang X, Fu J, Xing L, et al. Reasons, efficacy and safety of switching to Dolutegravir-Based regimens among virologically suppressed PLWH: A retrospective cohort study of 96 weeks. Infect Drug Resist. 2024;17:1571.","journal-title":"Infect Drug Resist"},{"issue":"3","key":"11710_CR30","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/jppr.1392","volume":"48","author":"JZ Low","year":"2018","unstructured":"Low JZ, Khoo SP, Nor Azmi N, Chong ML, Sulaiman H, Azwa I, et al. Is the risk of tenofovir-induced nephrotoxicity similar in treatment-na\u00efve compared to treatment-experienced patients? J Pharm Pract Res. 2018;48(3):242\u201350.","journal-title":"J Pharm Pract Res"},{"issue":"5","key":"11710_CR31","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.jmii.2019.07.003","volume":"52","author":"Q Tan","year":"2019","unstructured":"Tan Q, He YH, Yang TT, Yan DM, Wang Y, Zhao X, et al. Effects of long-term exposure to Tenofovir disoproxil fumarate-containing antiretroviral therapy on renal function in HIV-positive Chinese patients. J Microbiol Immunol Infect. 2019;52(5):710\u20139.","journal-title":"J Microbiol Immunol Infect"},{"issue":"2","key":"11710_CR32","doi-asserted-by":"publisher","first-page":"226","DOI":"10.3947\/ic.2023.0001","volume":"55","author":"S Srisopa","year":"2023","unstructured":"Srisopa S, Kornjirakasemsan A, Treebupachatsakul P, Sonthisombat P. Incidence and risk factors of tenofovir disoproxil fumarate induced nephrotoxicity and renal function recovery, a hospital case-control study. Infect Chemother. 2023;55(2):226\u201336.","journal-title":"Infect Chemother"},{"issue":"4","key":"11710_CR33","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1093\/cid\/ciu869","volume":"60","author":"KN Althoff","year":"2015","unstructured":"Althoff KN, McGinnis KA, Wyatt CM, Freiberg MS, Gilbert C, Oursler KK, et al. Comparison of risk and age at diagnosis of myocardial infarction, end-stage renal disease, and non-AIDS-defining cancer in HIV-infected versus uninfected adults. Clin Infect Dis. 2015;60(4):627\u201338.","journal-title":"Clin Infect Dis"},{"issue":"7","key":"11710_CR34","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.2215\/CJN.09191010","volume":"6","author":"P Flandre","year":"2011","unstructured":"Flandre P, Pugliese P, Cuzin L, Bagnis CI, Tack I, Cabi\u00e9 A, et al. Risk factors of chronic kidney disease in HIV-infected patients. Clin J Am Soc Nephrol. 2011;6(7):1700\u20137.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"11710_CR35","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/j.1468-1293.2012.01036.x","volume":"14","author":"A Ganesan","year":"2013","unstructured":"Ganesan A, Krantz EM, Huppler Hullsiek K, Riddle MS, Weintrob AC, Lalani T, et al. Determinants of incident chronic kidney disease and progression in a cohort of HIV-infected persons with unrestricted access to health care. HIV Med. 2013;14(2):65\u201376.","journal-title":"HIV Med"},{"key":"11710_CR36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0162320","author":"G Lapadula","year":"2016","unstructured":"Lapadula G, Bernasconi DP, Casari S, Maggiolo F, Cauda R, Di Pietro M, et al. Risk of chronic kidney disease among patients developing mild renal impairment during tenofovir-containing antiretroviral treatment. PLoS ONE. 2016. https:\/\/doi.org\/10.1371\/journal.pone.0162320.","journal-title":"PLoS ONE"},{"issue":"6","key":"11710_CR37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0066223","volume":"8","author":"P Morlat","year":"2013","unstructured":"Morlat P, Vivot A, Vandenhende MA, Dauchy FA, Asselineau J, D\u00e9ti E, et al. Role of traditional risk factors and antiretroviral drugs in the incidence of chronic kidney disease, ANRS CO3 Aquitaine Cohort, France, 2004\u20132012. PLoS ONE. 2013;8(6):e66223.","journal-title":"PLoS ONE"},{"issue":"10","key":"11710_CR38","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1097\/QAD.0000000000002570","volume":"34","author":"A Mocroft","year":"2020","unstructured":"Mocroft A, Ryom L, Oprea C, Li Q, Rauch A, Boesecke C, et al. Influence of hepatitis C virus co-infection and hepatitis C virus treatment on risk of chronic kidney disease in HIV-positive persons. AIDS. 2020;34(10):1485\u201395.","journal-title":"AIDS"},{"issue":"3","key":"11710_CR39","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1089\/apc.2016.0286","volume":"31","author":"S Suzuki","year":"2017","unstructured":"Suzuki S, Nishijima T, Kawasaki Y, Kurosawa T, Mutoh Y, Kikuchi Y, et al. Effect of Tenofovir disoproxil fumarate on incidence of chronic kidney disease and rate of estimated glomerular filtration rate decrement in HIV-1-infected treatment-na\u00efve Asian patients: results from 12-year observational cohort. AIDS Patient Care STDS. 2017;31(3):105\u201312.","journal-title":"AIDS Patient Care STDS"},{"issue":"3","key":"11710_CR40","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1007\/s10157-018-1644-5","volume":"23","author":"B Mat\u0142osz","year":"2019","unstructured":"Mat\u0142osz B, Pietraszkiewicz E, Firl\u0105g-Burkacka E, Grycner E, Horban A, Kowalska JD. Risk factors for kidney disease among HIV-1 positive persons in the methadone program. Clin Exp Nephrol. 2019;23(3):342\u20138.","journal-title":"Clin Exp Nephrol"},{"issue":"6","key":"11710_CR41","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1111\/j.1468-1293.2008.00691.x","volume":"10","author":"LJ Campbell","year":"2009","unstructured":"Campbell LJ, Ibrahim F, Fisher M, Holt SG, Hendry BM, Post FA. Spectrum of chronic kidney disease in HIV-infected patients. HIV Med. 2009;10(6):329\u201336.","journal-title":"HIV Med"},{"issue":"5","key":"11710_CR42","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1007\/s11096-015-0132-1","volume":"37","author":"PR Quesada","year":"2015","unstructured":"Quesada PR, Esteban LL, Garc\u00eda JR, S\u00e1nchez RV, Garc\u00eda TM, Alonso-Vega GG, et al. Incidence and risk factors for tenofovir-associated renal toxicity in HIV-infected patients. Int J Clin Pharm. 2015;37(5):865\u201372.","journal-title":"Int J Clin Pharm"},{"issue":"7","key":"11710_CR43","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1097\/QAD.0b013e328351f68f","volume":"26","author":"R Scherzer","year":"2012","unstructured":"Scherzer R, Estrella M, Li Y, Choi AI, Deeks SG, Grunfeld C, et al. Association of tenofovir exposure with kidney disease risk in HIV infection. AIDS. 2012;26(7):867\u201375.","journal-title":"AIDS"},{"issue":"1","key":"11710_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12879-017-2350-8","volume":"17","author":"C Rossi","year":"2017","unstructured":"Rossi C, Raboud J, Walmsley S, Cooper C, Antoniou T, Burchell AN, et al. Hepatitis C co-infection is associated with an increased risk of incident chronic kidney disease in HIV-infected patients initiating combination antiretroviral therapy. BMC Infect Dis. 2017;17(1):1\u201310.","journal-title":"BMC Infect Dis"},{"key":"11710_CR45","doi-asserted-by":"crossref","unstructured":"Yu Z, Rebholz CM, Wong E, Chen Y, Matsushita K, Coresh J et al. Association Between Hypertension and Kidney Function Decline: The Atherosclerosis Risk in Communities (ARIC) Study. Am J Kidney Dis [Internet]. 2019 Sep 1 [cited 2025 Mar 5];74(3):310. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC6760841\/","DOI":"10.1053\/j.ajkd.2019.02.015"},{"key":"11710_CR46","doi-asserted-by":"crossref","unstructured":"Stengel B. Hypertension and glomerular function decline: the chicken or the egg? Kidney Int [Internet]. 2016 Aug 1 [cited 2025 Mar 5];90(2):254\u20136. Available from: https:\/\/www.kidney-international.org\/action\/showFullText?pii=S0085253816301776","DOI":"10.1016\/j.kint.2016.04.016"},{"issue":"1","key":"11710_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12879-021-06851-9","volume":"21","author":"A Twimukye","year":"2021","unstructured":"Twimukye A, Laker M, Odongpiny EAL, Ajok F, Onen H, Kalule I, et al. Patient experiences of switching from Efavirenz- to Dolutegravir-based antiretroviral therapy: a qualitative study in Uganda. BMC Infect Dis. 2021;21(1):1\u201314.","journal-title":"BMC Infect Dis"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-11710-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-025-11710-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-11710-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:47:43Z","timestamp":1761119263000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-025-11710-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,22]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["11710"],"URL":"https:\/\/doi.org\/10.1186\/s12879-025-11710-y","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,22]]},"assertion":[{"value":"16 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol and informed consent form were approved by the Ethics Committee of the Faculty of Medicine, Universitas Indonesia and Cipto Mangunkusumo Hospital (No: KET\u2013255\/UN2.F1\/ETIK\/PPM.00.02\/2023). Written informed consent statements for participation were received from all participants prior to enrollment in the study. All participants were anonymized before data processing and all methods were done according to the Declaration of Helsinki. This study is not a clinical trial. Hence, clinical trial number is not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Consent statements for publication have been received from all respective participants prior to the study enrollment. All authors consent to publish this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1386"}}